Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy

Core Insights - Alnylam Pharmaceuticals has launched a new five-year strategy called 'Alnylam 2030' aimed at scaling operations and achieving profitable growth while focusing on leadership in transthyretin (TTR) amyloidosis [1][2] Financial Projections - The company projects its 2026 combined net product revenue to be between $4.9 billion and $5.3 billion, with the majority coming from TTR and the Rare segment expected to contribute around $500-$600 million [3] - Alnylam aims for a revenue compound annual growth rate (CAGR) of over 25% through 2030 and a non-GAAP operating margin of nearly 30% [2][3] Product Development - Alnylam plans to launch the next-generation RNAi silencer, nucresiran, targeting polyneuropathy by 2028 and cardiomyopathy by 2030 [2] - The launch of Amvuttra in TTR-CM is anticipated to be a significant catalyst for revenue growth in 2026 [3] Company Overview - Alnylam Pharmaceuticals is a leading biotech firm focused on discovering, developing, and commercializing therapeutics based on ribonucleic acid interference, with a mission to develop transformative therapies to prevent or reverse diseases [4]